PR
ELV icon

Payden & Rygel’s Elevance Health ELV Stock Holding History

Payden & Rygel’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,900
Closed -$18.8M – 133
2023
Q1 		$18.8M Sell
40,900
-27,000
-40% -$12.8M 1.11% 42
2022
Q4 		$34.8M Buy
67,900
+1,500
+2% +$762K 1.86% 13
2022
Q3 		$30.2M Buy
66,400
+27,200
+69% +$13M 1.76% 15
2022
Q2 		$18.9M Buy
39,200
+35,400
+932% +$17.5M 1.14% 43
2022
Q1 		$1.87M Buy
3,800
+1,900
+100% +$868K 0.09% 81
2021
Q4 		$881K Sell
1,900
-63,200
-97% -$26.6M 0.04% 97
2021
Q3 		$24.3M Sell
65,100
-200
-0.3% -$76K 1.26% 34
2021
Q2 		$24.9M Buy
65,300
+100
+0.2% +$38.2K 1.19% 42
2021
Q1 		$23.4M Buy
+65,200
New +$21M 1.09% 47

Other funds holding ELV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Payden & Rygel's ELV Position: Q2 2023 in Review

Payden & Rygel sold out of Elevance Health (ELV) in Q2 2023, closing a stake of 40,900 shares — an estimated $18.8M sold.

Payden & Rygel first reported a position in ELV in Q1 2021 and held it in 9 quarters. The position peaked at $34.8M in Q4 2022. 1,523 funds tracked by Wall St. Rank hold ELV as of Q2 2023.

  • Payden & Rygel reported no remaining Elevance Health position as of Q2 2023 after selling out during the quarter.
  • Payden & Rygel sold 40,900 Elevance Health shares in Q2 2023, an estimated $18.8M.
  • Payden & Rygel first reported a position in Elevance Health in Q1 2021 and held it in 9 quarters.
  • Payden & Rygel's Elevance Health position peaked at $34.8M in Q4 2022.
  • 1,523 funds tracked by Wall St. Rank held Elevance Health as of Q2 2023.

Based on Payden & Rygel's 13F filing for Q2 2023, filed 10 Aug 2023.